Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242008 · ClinicalTrials.gov registry record · Phase 3
A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00242008: Completed Phase 3 study, sponsored by UCB Pharma.
NCT00242008 is a Phase 3 study that has completed, run by UCB Pharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242008, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this trial is to assess whether it is possible for subjects with idiopathic Parkinson's Disease to switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal system (SPM 962) overnight without worsening of Parkinson's Disease symptoms. Subjects who meet eligibility criteria will be switched overnight to treatment with rotigotine transdermal patches at a dose considered equivalent to the dose of dopamine agonist that the subject is currently taking. Subjects on ropinirole or pramipexole will take their last dose at bedtime and then apply rotigotine patch(es) upon awakening the next morning. Subjects on cabergoline will apply rotigotine patches 24 hours after the final dose of cabergoline. Subjects will continue rotigotine treatment for 28 days, during which dose can be increased or decreased as needed. At the end of treatment, subjects can select to enroll in an open-label extension trial. The first subject was enrolled on 28 December 2004. The last subject was enrolled in June 2005 and the last subject visit was conducted in July 2005. This study is now closed.
Interventions
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-12 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
What the finished NCT00242008 record still lists
NCT00242008 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Rotigotine is the first listed.
NCT00242008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00242008 about?
NCT00242008 is a clinical study titled "A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease". The purpose of this trial is to assess whether it is possible for subjects with idiopathic Parkinson's Disease to switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal system (SPM 962) overnight without worsening of Parkinson's Disease symptoms. Subjects who meet eligibility...
What is the current status of trial NCT00242008?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-12. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00242008?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00242008?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia